title: O/W lipid emulsions for parenteral drug delivery. III. Lipophilicity necessary for incorporation in oil particles even after intravenous injection.
abstract: The potential usefulness of oil-in-water (O/W) lipid emulsions as injectable drug delivery systems was examined. Plasma concentrations of oil particles after intravenous injection of a standard lipid emulsion composed of soybean oil and egg yolk phosphatides were monitored based on the plasma concentrations of phospholipids and triglycerides, and the light scattering intensity of the plasma. Their time profiles were similar to each other, and the oil particle size decreased time-dependently. Pretreatment with dextran sulfate, a known reticuloendothelial system (RES) suppressor, resulted in marked reduction of the plasma clearance of the oil particles and of the time-dependent alteration of oil particle size, suggesting that oil particles were trapped by RES. The lipophilicity of the drug needed for its incorporation in the oil particles even after intravenous injection was found to be clog P > 8, where clog P is the calculated logarithm of the partition coefficient between n-octanol and water. In the case of sudan II (clog P = 5.4), the release from the oil particles was very quick after intravenous injection, resulting in slight alteration in biodistribution when compared with its micellar solution. In contrast, menatetrenone (clog P = 9.5) was selectively delivered to the liver, lungs and spleen, being consistent with the oil particles taken up by RES.
authors.affiliation: Shionogi Research Laboratories, Shionogi & Co., Ltd., Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Sakaeda
authors.forename: K
authors.initials: K
authors.lastname: Hirano
mesh_terms: D000758:Anesthesia; D000818:Animals; D001391:Azo Compounds / Q000493:pharmacokinetics; D016264:Dextran Sulfate / Q000494:pharmacology; D016503:Drug Delivery Systems / Q000379:methods*; D004530:Egg Yolk / Q000378:metabolism; D005217:Fat Emulsions, Intravenous / Q000493:pharmacokinetics*; D006490:Hemostatics / Q000493:pharmacokinetics; D066298:In Vitro Techniques; D008297:Male; D012157:Mononuclear Phagocyte System / Q000378:metabolism*; D010743:Phospholipids / Q000097:blood / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar; D012542:Scattering, Radiation; D012995:Solubility; D013024:Soybean Oil / Q000493:pharmacokinetics; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014812:Vitamin K / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D024482:Vitamin K 2 / Q000031:analogs & derivatives
chemical_list: D001391:Azo Compounds; D005217:Fat Emulsions, Intravenous; D006490:Hemostatics; D010743:Phospholipids; D014280:Triglycerides; D024482:Vitamin K 2; D014812:Vitamin K; C030814:menatetrenone; D013024:Soybean Oil; C033003:sudan red; D016264:Dextran Sulfate